Comparison of the resonance sonorheometry based Quantra® system with rotational thromboelastometry ROTEM® sigma in cardiac surgery - a prospective observational study.


Journal

BMC anesthesiology
ISSN: 1471-2253
Titre abrégé: BMC Anesthesiol
Pays: England
ID NLM: 100968535

Informations de publication

Date de publication:
28 10 2021
Historique:
received: 24 03 2021
accepted: 28 08 2021
entrez: 29 10 2021
pubmed: 30 10 2021
medline: 24 2 2022
Statut: epublish

Résumé

Measures of the sonorheometry based Quantra® viscoelastic hemostatic analyzer (HemoSonics, LCC, Charlottesville, VA, USA) were compared with corresponding results of the ROTEM® sigma device (Instrumentation Laboratory, Bedford, MA, USA). In thirty-eight patients scheduled for elective cardiac surgery between December 2018 and October 2019, blood samples were taken after induction of anesthesia (sample 1) and after heparin neutralization (sample 2) and measured on Quantra (QPlus® Cartridge) and ROTEM sigma (ROTEM® sigma complete + hep Cartridge). Clot times and clot stiffness values were recorded. Clot stiffness values of ROTEM amplitudes (A in mm) were converted to shear modulus (G) in hectoPascal (hPa): G (hPa) = (5 x A)/(100-A). Additionally, time-to-results was recorded. Spearman rank test correlation and Bland Altman analysis were performed. Clot stiffness parameters of the Quantra correlated strongly with corresponding measurements of the ROTEM with r = 0.93 and 0.94 for EXTEM A10 vs CS and r = 0.94 and 0.96 for FIBTEM A10 vs FCS for sample 1 and 2, respectively. Quantra clot time correlated strongly with ROTEM INTEM CT with r = 0.71 for sample 1 and r = 0.75 for sample 2. However, Bland Altman analysis showed no agreement in all compared assays of both methods. The median time to delivery of first and complete results was significantly shorter for Quantra (412 and 658 s) compared to ROTEM sigma (839 and 1290 s). The Quantra showed a strong correlation with the ROTEM sigma for determining clot times and clot stiffness and the parameters assess similar aspects of clot development. However, these parameters are not directly interchangeable and implicate that separate cut-off values need to be established for users of the Quantra device. Word count: 278. The study was retrospectively registered with ClinicalTrials.gov (ID: NCT04210830 ) at December 20th 2019.

Sections du résumé

BACKGROUND
Measures of the sonorheometry based Quantra® viscoelastic hemostatic analyzer (HemoSonics, LCC, Charlottesville, VA, USA) were compared with corresponding results of the ROTEM® sigma device (Instrumentation Laboratory, Bedford, MA, USA).
METHODS
In thirty-eight patients scheduled for elective cardiac surgery between December 2018 and October 2019, blood samples were taken after induction of anesthesia (sample 1) and after heparin neutralization (sample 2) and measured on Quantra (QPlus® Cartridge) and ROTEM sigma (ROTEM® sigma complete + hep Cartridge). Clot times and clot stiffness values were recorded. Clot stiffness values of ROTEM amplitudes (A in mm) were converted to shear modulus (G) in hectoPascal (hPa): G (hPa) = (5 x A)/(100-A). Additionally, time-to-results was recorded. Spearman rank test correlation and Bland Altman analysis were performed.
RESULTS
Clot stiffness parameters of the Quantra correlated strongly with corresponding measurements of the ROTEM with r = 0.93 and 0.94 for EXTEM A10 vs CS and r = 0.94 and 0.96 for FIBTEM A10 vs FCS for sample 1 and 2, respectively. Quantra clot time correlated strongly with ROTEM INTEM CT with r = 0.71 for sample 1 and r = 0.75 for sample 2. However, Bland Altman analysis showed no agreement in all compared assays of both methods. The median time to delivery of first and complete results was significantly shorter for Quantra (412 and 658 s) compared to ROTEM sigma (839 and 1290 s).
CONCLUSIONS
The Quantra showed a strong correlation with the ROTEM sigma for determining clot times and clot stiffness and the parameters assess similar aspects of clot development. However, these parameters are not directly interchangeable and implicate that separate cut-off values need to be established for users of the Quantra device. Word count: 278.
TRIAL REGISTRATION
The study was retrospectively registered with ClinicalTrials.gov (ID: NCT04210830 ) at December 20th 2019.

Identifiants

pubmed: 34711167
doi: 10.1186/s12871-021-01469-5
pii: 10.1186/s12871-021-01469-5
pmc: PMC8555139
doi:

Banques de données

ClinicalTrials.gov
['NCT04210830']

Types de publication

Comparative Study Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

260

Informations de copyright

© 2021. The Author(s).

Références

Clin Appl Thromb Hemost. 2017 Apr;23(3):201-210
pubmed: 26400661
Cochrane Database Syst Rev. 2011 Mar 16;(3):CD007871
pubmed: 21412912
Stat Methods Med Res. 1999 Jun;8(2):135-60
pubmed: 10501650
Lancet. 2007 Oct 20;370(9596):1453-7
pubmed: 18064739
Anesth Analg. 2016 Dec;123(6):1372-1379
pubmed: 27224934
J Cardiothorac Vasc Anesth. 2019 Jun;33(6):1590-1598
pubmed: 30737122
J Cardiothorac Vasc Anesth. 2018 Feb;32(1):141-150
pubmed: 29126688
J Appl Lab Med. 2020 Nov 1;5(6):1228-1241
pubmed: 32432668
Br J Anaesth. 2017 Jun 1;118(6):823-833
pubmed: 28475665
Psychol Methods. 2007 Dec;12(4):399-413
pubmed: 18179351
Anesth Analg. 2020 Apr;130(4):899-909
pubmed: 32032102
Br J Haematol. 2018 Sep;182(6):789-806
pubmed: 30073664
Anesth Analg. 2015 Oct;121(4):868-878
pubmed: 26378699
Ann Biomed Eng. 2016 May;44(5):1405-24
pubmed: 26399992
Anesth Analg. 2016 Dec;123(6):1390-1399
pubmed: 27749339
Thromb Haemost. 2014 Jun;111(6):1161-6
pubmed: 24477424
Anaesthesia. 2019 Mar;74(3):348-356
pubmed: 30575011
Anesth Analg. 2016 Dec;123(6):1400-1407
pubmed: 27159065
Anesth Analg. 2018 May;126(5):1763-1768
pubmed: 29481436

Auteurs

Werner Baulig (W)

Department of Anesthesiology and Intensive Care Medicine, Klinik Im Park, Seestrasse 220, CH-8027, Zurich, Switzerland. werner.baulig@hirslanden.ch.

Samira Akbas (S)

Institute of Anesthesiology, University Hospital, Zurich, Switzerland.

Philipp K Schütt (PK)

Department of Anesthesiology and Intensive Care Medicine, Klinik Im Park, Seestrasse 220, CH-8027, Zurich, Switzerland.

Wolfgang Keul (W)

Department of Anesthesiology and Intensive Care Medicine, Klinik Im Park, Seestrasse 220, CH-8027, Zurich, Switzerland.

Marija Jovic (M)

Department of Anesthesiology and Intensive Care Medicine, Klinik Im Park, Seestrasse 220, CH-8027, Zurich, Switzerland.

Pascal Berdat (P)

Department of Cardiac Surgery, Klinik Im Park, Zurich, Switzerland.

Stefanie von Felten (S)

Department of Biostatistics, Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland.

Klaus Steigmiller (K)

Department of Biostatistics, Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland.

Michael Thomas Ganter (MT)

Institute of Anesthesiology, Kantonsspital Winterthur, Winterthur, Switzerland.

Oliver M Theusinger (OM)

Medical Department, OSEARA health care medicine, Kloten, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH